Equities researchers at StockNews.com began coverage on shares of Inuvo (NYSE:INUV – Get Free Report) in a research report issued on Wednesday. The firm set a “hold” rating on the stock.
Separately, LADENBURG THALM/SH SH began coverage on Inuvo in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $1.00 target price on the stock.
View Our Latest Stock Analysis on Inuvo
Inuvo Stock Performance
Inuvo (NYSE:INUV – Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter. The firm had revenue of $20.84 million during the quarter. Inuvo had a negative net margin of 14.06% and a negative return on equity of 56.15%. Sell-side analysts predict that Inuvo will post 0.01 EPS for the current year.
Institutional Trading of Inuvo
An institutional investor recently raised its position in Inuvo stock. Procyon Advisors LLC increased its holdings in Inuvo, Inc. (NYSE:INUV – Free Report) by 121.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 61,600 shares of the company’s stock after purchasing an additional 33,827 shares during the period. Procyon Advisors LLC’s holdings in Inuvo were worth $26,000 as of its most recent SEC filing. 29.36% of the stock is currently owned by institutional investors and hedge funds.
About Inuvo
Inuvo, Inc engages in the advertising technology and services business primarily in the United States. It sells information technology solutions to brands, agencies, and large consolidators of advertising demand (platforms). Its platforms optimize the purchase and placement of advertising in real time.
Read More
- Five stocks we like better than Inuvo
- How to Most Effectively Use the MarketBeat Earnings Screener
- Garmin Navigates to New Highs Driven By Wearables Trend
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Inuvo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inuvo and related companies with MarketBeat.com's FREE daily email newsletter.